

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Mangalam Drugs & Organics Limited		
Name(s) of the acquirer/seller and Persons Acting in Concert (PAC) with the Acquirer/seller	Ipca Laboratories Limited		
Whether the acquirer / seller belongs to Promoter / Promoter Group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	Bombay Stock Exchange Ltd. & National Stock Exchange of India Ltd.		
Details of the acquisition / disposal as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition / sale under consideration, holding of			
a. Shares carrying voting rights	62,557	0.47%	0.47%
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	62,557	0.47%	0.47%
Details of Acquisition / Sale			
a. Shares carrying voting rights acquired / sold	62,557	0.47%	0.47%
b. VRs acquired/ sold otherwise than by shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold	Nil	Nil	Nil
d. Shares encumbered / invoked / released by the acquirer	Nil	Nil	Nil
e. Total (a+b+c+/-d)	62,557	0.47%	0.47%

Rohe

Ipca Laboratories Ltd.
www.ipca.com


After the acquisition/sale, holding of			
a. Shares carrying voting rights	Nil	Nil	Nil
b. Shares encumbered with the acquirer	Nil	Nil	Nil
c. VRs otherwise than by shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	Nil	Nil	Nil
Mode of acquisition / sale (eg. Open market/off market/public issue/rights issue/preferential allotment/inter-se transfer etc.)	Open market		
Date of acquisition/sale of shares/VR or date of receipt of intimation of allotment of shares, whichever is applicable	05.06.2015, 08.06.2015, 09.06.2015, 10.06.2015 and 19.06.2015		
Equity share capital/total voting capital of the TC before the said acquisition/sale	1,31,78,248	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition/sale	1,31,78,248	100%	100%
Total diluted share/voting capital of the TC after the said acquisition/sale	1,31,78,248	100%	100%

(*) Total share capital/voting capital to be taken as per the latest filing done by the Company to the Stock Exchange under Clause 35 of the Listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the acquirer / seller / Authorised Signatory:

For Ipca Laboratories Ltd.



Harish P. Kamath
Company Secretary

Place: Mumbai

Date: 23rd June, 2015

Ipca Laboratories Ltd.
www.ipca.com